Kazia Therapeutics (KZIA) EBT Margin (2011 - 2017)

Kazia Therapeutics' EBT Margin history runs 6 years deep, the most recent figure standing at 123.34% for Q2 2017.

• Quarterly EBT Margin rose 17523.0% year-over-year to 123.34% in Q2 2017, while the trailing twelve-month figure through Jun 2017 was 214.23% (up 2837.0% YoY) and the FY2025 annual result came in at 53447.62%, down 5228705.0% from the prior year.
• EBT Margin was 123.34% for Q2 2017 at Kazia Therapeutics, up from 298.58% in the prior quarter.
• Across five years, EBT Margin topped out at 87.17% in Q4 2013 and bottomed at 298.58% in Q2 2016.
• A 4-year average of 212.95% and a median of 257.07% in 2015 frame the typical range for EBT Margin.
• Annual changes were most pronounced in 2016 — EBT Margin slumped 4150 bps — and 2017, when it jumped 17523 bps.
• Kazia Therapeutics' EBT Margin stood at 87.17% in 2013, then slumped by 195 bps to 257.07% in 2015, then decreased by 16 bps to 298.58% in 2016, then soared by 59 bps to 123.34% in 2017.
• Business Quant data shows KZIA's EBT Margin at 123.34% in Q2 2017, 298.58% in Q4 2016, and 298.58% in Q2 2016.